First Multicenter, Randomized Phase 3 Study in Patients (Pts) with Relapsed/Refractory (R/R) Peripheral T-Cell Lymphoma (PTCL): Alisertib (MLN8237) Versus Investigator's Choice (Lumiere trial; NCT01482962)

Owen A. O’Connor, Andrei R. Shustov, Francesco d’Amore et al.|Blood|2015

Cited by 24